153 related articles for article (PubMed ID: 10415067)
1. Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2.
Rafi-Janajreh AQ; Chen D; Schmits R; Mak TW; Grayson RL; Sponenberg DP; Nagarkatti M; Nagarkatti PS
J Immunol; 1999 Aug; 163(3):1619-27. PubMed ID: 10415067
[TBL] [Abstract][Full Text] [Related]
2. Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome.
Rafi AQ; Zeytun A; Bradley MJ; Sponenberg DP; Grayson RL; Nagarkatti M; Nagarkatti PS
J Immunol; 1998 Sep; 161(6):3077-86. PubMed ID: 9743374
[TBL] [Abstract][Full Text] [Related]
3. Blockade of hyaluronan inhibits IL-2-induced vascular leak syndrome and maintains effectiveness of IL-2 treatment for metastatic melanoma.
Guan H; Nagarkatti PS; Nagarkatti M
J Immunol; 2007 Sep; 179(6):3715-23. PubMed ID: 17785808
[TBL] [Abstract][Full Text] [Related]
4. Role of CD44 in lymphokine-activated killer cell-mediated killing of melanoma.
Sun J; Law GP; McKallip RJ
Cancer Immunol Immunother; 2012 Mar; 61(3):323-34. PubMed ID: 21901391
[TBL] [Abstract][Full Text] [Related]
5. Cooperation between CD44 and LFA-1/CD11a adhesion receptors in lymphokine-activated killer cell cytotoxicity.
Matsumoto G; Nghiem MP; Nozaki N; Schmits R; Penninger JM
J Immunol; 1998 Jun; 160(12):5781-9. PubMed ID: 9637488
[TBL] [Abstract][Full Text] [Related]
6. Regulation of interleukin-2-induced vascular leak syndrome by targeting CD44 using hyaluronic acid and anti-CD44 antibodies.
Mustafa A; McKallip RJ; Fisher M; Duncan R; Nagarkatti PS; Nagarkatti M
J Immunother; 2002; 25(6):476-88. PubMed ID: 12439345
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
8. Constitutive expression of IL-2Rbeta chain and its effects on IL-2-induced vascular leak syndrome.
Assier E; Jullien V; Lefort J; Moreau JL; Vargaftig BB; Lapa e Silva JR; Thèze J
Cytokine; 2005 Dec; 32(6):280-6. PubMed ID: 16378732
[TBL] [Abstract][Full Text] [Related]
9. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.
Rosenstein M; Ettinghausen SE; Rosenberg SA
J Immunol; 1986 Sep; 137(5):1735-42. PubMed ID: 3528289
[TBL] [Abstract][Full Text] [Related]
10. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.
Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
J Immunol; 1985 Aug; 135(2):1488-97. PubMed ID: 3891854
[TBL] [Abstract][Full Text] [Related]
11. Inducible nitric oxide synthase (iNOS) is not required for IL-2-induced hypotension and vascular leak syndrome in mice.
Kondapaneni M; McGregor JR; Salvemini D; Laubach VE; Samlowski WE
J Immunother; 2008 May; 31(4):325-33. PubMed ID: 18391763
[TBL] [Abstract][Full Text] [Related]
12. Lymphokine activated killer (LAK) cell-mediated endothelial injury: a mechanism for capillary leak syndrome in patients treated with LAK cells and interleukin-2.
Kotasek D; Vercellotti GM; Ochoa AC; Bach FH; Jacob HS
Trans Assoc Am Physicians; 1987; 100():21-7. PubMed ID: 3502662
[TBL] [Abstract][Full Text] [Related]
13. Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by interleukin-2-activated cytolytic lymphocytes.
McKallip RJ; Fisher M; Do Y; Szakal AK; Gunthert U; Nagarkatti PS; Nagarkatti M
J Biol Chem; 2003 Oct; 278(44):43818-30. PubMed ID: 12904302
[TBL] [Abstract][Full Text] [Related]
14. Role of CD4(+)CD25(+) T regulatory cells in IL-2-induced vascular leak.
Melencio L; McKallip RJ; Guan H; Ramakrishnan R; Jain R; Nagarkatti PS; Nagarkatti M
Int Immunol; 2006 Oct; 18(10):1461-71. PubMed ID: 16914509
[TBL] [Abstract][Full Text] [Related]
15. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
[TBL] [Abstract][Full Text] [Related]
16. Regulation of cell morphology in B lymphocytes by IL-4: evidence for induced cytoskeletal changes.
Davey EJ; Thyberg J; Conrad DH; Severinson E
J Immunol; 1998 Jun; 160(11):5366-73. PubMed ID: 9605136
[TBL] [Abstract][Full Text] [Related]
17. Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo.
Puri RK; Travis WD; Rosenberg SA
Cancer Res; 1989 Feb; 49(4):969-76. PubMed ID: 2783561
[TBL] [Abstract][Full Text] [Related]
18. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
19. CD44 disruption prevents degeneration of the capillary network in obstructive nephropathy via reduction of TGF-beta1-induced apoptosis.
Rouschop KM; Claessen N; Pals ST; Weening JJ; Florquin S
J Am Soc Nephrol; 2006 Mar; 17(3):746-53. PubMed ID: 16452493
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of cultured endothelial injury induced by lymphokine-activated killer cells.
Kotasek D; Vercellotti GM; Ochoa AC; Bach FH; White JG; Jacob HS
Cancer Res; 1988 Oct; 48(19):5528-32. PubMed ID: 3262010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
